Changchun Institute of Biological Products Co Ltd is a time-honored drug company in North China's Jilin province. [Photo/ccbio.net]

Changchun Institute of Biological Products Co Ltd is a State-owned bio-tech corporation that produces, develops, and sells biological products.

Founded in 1946 and situated in Changchun, capital city of Jilin province, the firm occupies an area of 109,700 square meters, having assets worth 1.6 billion yuan ($240 million) and over 900 staff members, among whom over 73.3 percent hold college or higher degrees. The firm's annual output of vaccines and other genetic engineering products reaches 100 million doses.

The products of Changchun Institute of Biological Products Co Ltd have won the second-place prize of the National Prize for Progress in Science and Technology, the second-place prize of the National Award for Technological Invention, and the first-place prize of the Jilin Provincial Award for Scientific and Technological Progress.

The firm is China's first pilot trail base of interferon and China's first industrial production base of hepatitis B vaccines.

In 1992, Changchun Institute of Biological Products Co Ltd was allowed by the government to confer master's degree certificates, and it now boasts two postgraduate disciplines – medical immunology and Pathology and Microbiology, with more than 200 master's students having graduated from the institute. In 2001, the institute was allowed to establish its own post-doctoral research center.

Changchun Institute of Biological Products Co Ltd is dedicated to developing biological products, prioritizing people's lives and health, and making a major contribution to China's disease prevention and control efforts.